TY - JOUR
T1 - Treatment of chronic hepatitis C with interferon alone or combined with ribavirin in Japan
AU - Kumada, Takashi
AU - Toyoda, Hidenori
AU - Honda, Takashi
AU - Kuzuya, Teiji
AU - Katano, Yosiaki
AU - Nakano, Isao
AU - Goto, Hidemi
PY - 2006
Y1 - 2006
N2 - We treated 665 patients with chronic hepatitis C with interferon (IFN) monotherapy and 288 with combined IFN and ribavirin. At the baseline, age (53.8 ± 11.1 vs. 49.7 ± 10.5 years, p < 0.0001) and activity (p = 0.0207) as well as fibrosis (p = 0.0270) were higher in patients who received combination therapy than in those receiving monotherapy. Compliance to treatment (64.2 vs. 62.1%, p < 0.0001) and discontinuation were more frequent (18.1 vs. 14.5%, p < 0.0001) in patients with combination therapy than in those with monotherapy. Patients with combination therapy with genotype 2 infection achieved sustained viral response (SVR) at a rate of 77.0%, regardless of viral loads, in contrast to those with genotype 1 infection, of whom only 24.4% gained SVR. Of patients with combination therapy, reduction (42.6 vs. 29.0%, p = 0.0453) and discontinuation (34.0 vs. 21.6%, p = 0.0414) of ribavirin were more frequently required in the 47 patients ≥65 years than in the 241 patients <65 years. Although a trend for higher SVR to combination therapy was observed in patients aged <65 than in those aged ≥65 years (39.4 vs. 25.2%), the difference was not significant (p = 0.0819). In patients with genotype 1 infection, IFN monotherapy in addition to the 24-week combination therapy increased the SVR rate (18.3 vs. 42.6%, p = 0.0003). A decrease in SVR was observed with an increased body mass index in patients who received combination therapy.
AB - We treated 665 patients with chronic hepatitis C with interferon (IFN) monotherapy and 288 with combined IFN and ribavirin. At the baseline, age (53.8 ± 11.1 vs. 49.7 ± 10.5 years, p < 0.0001) and activity (p = 0.0207) as well as fibrosis (p = 0.0270) were higher in patients who received combination therapy than in those receiving monotherapy. Compliance to treatment (64.2 vs. 62.1%, p < 0.0001) and discontinuation were more frequent (18.1 vs. 14.5%, p < 0.0001) in patients with combination therapy than in those with monotherapy. Patients with combination therapy with genotype 2 infection achieved sustained viral response (SVR) at a rate of 77.0%, regardless of viral loads, in contrast to those with genotype 1 infection, of whom only 24.4% gained SVR. Of patients with combination therapy, reduction (42.6 vs. 29.0%, p = 0.0453) and discontinuation (34.0 vs. 21.6%, p = 0.0414) of ribavirin were more frequently required in the 47 patients ≥65 years than in the 241 patients <65 years. Although a trend for higher SVR to combination therapy was observed in patients aged <65 than in those aged ≥65 years (39.4 vs. 25.2%), the difference was not significant (p = 0.0819). In patients with genotype 1 infection, IFN monotherapy in addition to the 24-week combination therapy increased the SVR rate (18.3 vs. 42.6%, p = 0.0003). A decrease in SVR was observed with an increased body mass index in patients who received combination therapy.
UR - http://www.scopus.com/inward/record.url?scp=24944552848&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=24944552848&partnerID=8YFLogxK
U2 - 10.1159/000087273
DO - 10.1159/000087273
M3 - Article
C2 - 16166799
AN - SCOPUS:24944552848
SN - 0300-5526
VL - 49
SP - 112
EP - 118
JO - Intervirology
JF - Intervirology
IS - 1-2
ER -